Average Reviews:
(More customer reviews)The book seems to be missing some chapters?!?! For example, how exactly to 'handicap' a phase III trial? It goes into no detail on the though process to establish a bullish, bearish, or neutral bias. Although it does clearly explain the ancillary information that might be required in analyzing a biotech company (cash burn, potential value, insider activity, and potential dates) it has no chapter or discussion on how to even begin to determine if a specific drug will pass/fail Phase III trial. Now granted that may be impossible to do in reality with a high degree of probability, but there is not a single case study of a trade to go through the entire process. Also missing is any discussion of how to obtain analysts estimates as a retail trader since most is only available to institutional clients.
That being said the book does do a decent enough job explaining what it does have chapters on including analyzing the cash positions of a firm and creating trading strategies around a specific bias. Unfortunately it never goes into how to exactly establish the bias via explanation or case studies.
Finally the author alludes to many possible potential short term trading opportunities such as a tendency for stocks and volatility around or after a specific announcement, but never elaborates on any. A chapter on this alone would've been worth 10x the price.
Mr Pelz has done a pretty good job with this one but it's only HALF COMPLETE. If the author reads this, please contact me!
Click Here to see more reviews about: The Biotech Trader Handbook (2nd Edition): A Fast, Simplified & Efficient Guide to Potentially Generate Outsized Returns in Biotech Using Options (for the non-scientist)
0 comments:
Post a Comment